Sovereign Financial Group Inc. Has $435,000 Holdings in Pfizer Inc. (NYSE:PFE)

Sovereign Financial Group Inc. cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,092 shares of the biopharmaceutical company’s stock after selling 1,363 shares during the quarter. Sovereign Financial Group Inc.’s holdings in Pfizer were worth $435,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Briaud Financial Planning Inc bought a new position in shares of Pfizer in the third quarter valued at $30,000. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer in the 3rd quarter valued at about $34,000. VisionPoint Advisory Group LLC raised its stake in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the period. GoalVest Advisory LLC increased its holdings in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer in the fourth quarter valued at $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PFE. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Morgan Stanley boosted their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $36.00.

Pfizer Trading Down 1.4 %

NYSE:PFE traded down $0.39 during trading hours on Tuesday, hitting $27.78. 65,400,901 shares of the company were exchanged, compared to its average volume of 43,591,664. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $157.28 billion, a price-to-earnings ratio of -462.84, a price-to-earnings-growth ratio of 1.17 and a beta of 0.63. The company has a fifty day simple moving average of $26.92 and a 200 day simple moving average of $28.12.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. Pfizer’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.23 earnings per share. Sell-side analysts expect that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.05%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.